📣 VC round data is live. Check it out!
- Public Comps
- Autobio Diagnostics
Autobio Diagnostics Valuation Multiples
Discover Autobio Diagnostics' revenue and EBITDA valuation multiples and investment history, alongside public comparables like Ambu, Carl Zeiss Meditec, Tecan Group, Insight Lifetech and more.
Autobio Diagnostics Overview
About Autobio Diagnostics
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, and sales of in vitro diagnostic reagents and instruments. The company’s main products include immunoassay, microbiological, molecular diagnostic, and biochemical reagents, along with immunoassay, microbiological, molecular detection, and mass spectrometry instruments, as well as auxiliary testing devices.
Founded
1999
HQ

Employees
5.8K
Website
Financials (LTM)
EV
$3B
Valuation Multiples
Start free trialAutobio Diagnostics Financials
Autobio Diagnostics reported last 12-month revenue of $639M and EBITDA of $247M.
In the same LTM period, Autobio Diagnostics generated $418M in gross profit, $247M in EBITDA, and $161M in net income.
Revenue (LTM)
Autobio Diagnostics P&L
In the most recent fiscal year, Autobio Diagnostics reported revenue of $625M and EBITDA of $251M.
Autobio Diagnostics is profitable as of last fiscal year, with gross margin of 66%, EBITDA margin of 40%, and net margin of 25%.
Financial data powered by Morningstar, Inc.
Autobio Diagnostics Stock Performance
Autobio Diagnostics has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Autobio Diagnostics' stock price is $4.70.
Autobio Diagnostics share price decreased by 4.9% in the last 30 days, and by 13.7% in the last year.
Autobio Diagnostics has an EPS (earnings per share) of $0.28.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | -1.0% | -4.9% | -4.2% | -13.7% | $0.28 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAutobio Diagnostics Valuation Multiples
Autobio Diagnostics trades at 4.0x EV/Revenue multiple, and 10.3x EV/EBITDA.
EV / Revenue (LTM)
Autobio Diagnostics Financial Valuation Multiples
As of June 4, 2026, Autobio Diagnostics has market cap of $3B and EV of $3B.
Autobio Diagnostics has a P/E ratio of 16.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Autobio Diagnostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Autobio Diagnostics Margins & Growth Rates
Autobio Diagnostics grew revenue by 7% and EBITDA by 2% in the last fiscal year.
In the most recent fiscal year, Autobio Diagnostics reported gross margin of 66%, EBITDA margin of 40%, and net margin of 25%.
Autobio Diagnostics Margins
Autobio Diagnostics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Autobio Diagnostics Operational KPIs
Autobio Diagnostics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Autobio Diagnostics' Rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Autobio Diagnostics' Rule of X is 56% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Autobio Diagnostics Competitors
Autobio Diagnostics competitors include Ambu, Carl Zeiss Meditec, Tecan Group, Insight Lifetech, Double Medical Technology, Sinbon Electronics, TransMedics, Haemonetics, MGI Tech and Integer Holdings.
Most Autobio Diagnostics public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.8x | 2.7x | 14.6x | 14.7x | |||
| 1.1x | 1.1x | 6.5x | 7.4x | |||
| 2.1x | 2.1x | 14.0x | 13.9x | |||
| 29.2x | - | 131.6x | - | |||
| 5.9x | 5.6x | 16.4x | 13.9x | |||
| 2.3x | 2.3x | 15.9x | 17.6x | |||
| 4.6x | 4.2x | 17.0x | 17.4x | |||
| 3.0x | 3.0x | 10.1x | 10.0x | |||
This data is available for Pro users. Sign up to see all Autobio Diagnostics competitors and their valuation data. Start Free Trial | ||||||
Investments by Autobio Diagnostics
Autobio Diagnostics has invested in 1 company to date.
Latest investment by Autobio Diagnostics was on December 17th 2018. Autobio Diagnostics invested in Mobidiag in their $12M Series A round (EV/Revenue multiple available to Pro users).
Latest Investments by Autobio Diagnostics
| Description | Mobidiag is a Keilaranta-headquartered Finnish-French biotechnology company offering qPCR and microarray tests for gastrointestinal infections, antibiotic resistance, HAIs, respiratory pathogens, and sepsis. Its automated platforms like Novodiag serve labs from small clinics to high-volume centers across Europe and beyond. |
| HQ Country | |
| HQ City | Espoo |
| Deal Date | 17 Dec 2018 |
| Round | Series A |
| Raised | $12M |
| Investors | Autobio Diagnostics |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Autobio Diagnostics investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Autobio Diagnostics
| When was Autobio Diagnostics founded? | Autobio Diagnostics was founded in 1999. |
| Where is Autobio Diagnostics headquartered? | Autobio Diagnostics is headquartered in China. |
| How many employees does Autobio Diagnostics have? | As of today, Autobio Diagnostics has over 5K employees. |
| Is Autobio Diagnostics publicly listed? | Yes, Autobio Diagnostics is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Autobio Diagnostics? | Autobio Diagnostics trades under 603658 ticker. |
| When did Autobio Diagnostics go public? | Autobio Diagnostics went public in 2016. |
| Who are competitors of Autobio Diagnostics? | Autobio Diagnostics main competitors include Ambu, Carl Zeiss Meditec, Tecan Group, Insight Lifetech, Double Medical Technology, Sinbon Electronics, TransMedics, Haemonetics, MGI Tech, Integer Holdings. |
| What is the current market cap of Autobio Diagnostics? | Autobio Diagnostics' current market cap is $3B. |
| What is the current revenue of Autobio Diagnostics? | Autobio Diagnostics' last 12 months revenue is $639M. |
| What is the current revenue growth of Autobio Diagnostics? | Autobio Diagnostics revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Autobio Diagnostics? | Current revenue multiple of Autobio Diagnostics is 4.0x. |
| What is the current EBITDA of Autobio Diagnostics? | Autobio Diagnostics' last 12 months EBITDA is $247M. |
| What is Autobio Diagnostics' EBITDA margin? | Autobio Diagnostics' last 12 months EBITDA margin is 39%. |
| What is the current EV/EBITDA multiple of Autobio Diagnostics? | Current EBITDA multiple of Autobio Diagnostics is 10.3x. |
| What is the current FCF of Autobio Diagnostics? | Autobio Diagnostics' last 12 months FCF is $276M. |
| What is Autobio Diagnostics' FCF margin? | Autobio Diagnostics' last 12 months FCF margin is 43%. |
| What is the current EV/FCF multiple of Autobio Diagnostics? | Current FCF multiple of Autobio Diagnostics is 9.2x. |
| How many companies Autobio Diagnostics has acquired to date? | Autobio Diagnostics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Autobio Diagnostics has invested to date? | As of June 2026, Autobio Diagnostics has invested in 1 company. |
| What was the last Autobio Diagnostics investment? | On 17th December 2018 Autobio Diagnostics invested in Mobidiag, participating in a $12M Series A round. |
| In what companies Autobio Diagnostics invested in? | Autobio Diagnostics invested in Mobidiag. |
See public comps similar to Autobio Diagnostics
Lists including Autobio Diagnostics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
